TLR2 expression and signaling-dependent inflammation impair wound healing in diabetic mice

Laboratory Investigation

Volumn 90, Issue 11, 2010, Pages 1628-1636

  Dasu, Mohan R ^a   Thangappan, Ravi K ^a   Bourgette, Alika ^b   Dipietro, Luisa A ^c   Isseroff, Rivkah ^a   Jialal, Ishwarlal ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

cytokines; inflammation; NF kB; Toll like receptor 2; type 1 diabetes; wound healing

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPERGLYCEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; WESTERN BLOTTING; WOUND; WOUND HEALING IMPAIRMENT;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MYELOID DIFFERENTIATION FACTOR 88; SIGNAL TRANSDUCTION; STREPTOZOCIN; TOLL-LIKE RECEPTOR 2; WOUND HEALING;

EID: 78049337495     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.158     Document Type: Article

References (45)

1. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet 2003;361: 1545-1551.
2. Boulton JM, Vileikyte L, Ragnarson-Tennvall G, et al. The global burden of diabetic foot disease. Lancet 2005;366:1719-1724.
3. Hogan P, Dall T, Nikolov P, et al. Economic costs of diabetes in the US. Diabetes Care 2002;26:917-932.
4. Johannesson A, Larsson GU, Ramstrand N, et al. Incidence of lower-limb amputation in the diabetic and nondiabetic general population: a 10-year population-based cohort study of initial unilateral and contralateral amputations and reamputations. Diabetes Care 2009;32: 275-280.
5. Falanga V. Wound healing and its impairment in diabetic foot. Lancet 2005;366:1736-1743.
6. Goova MT, Li J, Kislinger T, et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001;159:513-525.
7. Liu R, Bal HS, Desta T, et al. Tumor necrosis factor-alpha mediates diabetes-enhanced apoptosis of matrix-producing cells and impairs diabetic healing. Am J Pathol 2006;168:757-764.
8. Goren I, Mü ller E, Pfeilschifter J, et al. Severely impaired insulin signaling in chronic wounds of diabetic ob/ob mice: a potential role of tumor necrosis factor-alpha. Am J Pathol 2006;168:765-777.
9. Mertz PM, Sauder DL, Davis SC, et al. IL-1 as a potent inducer of wound re-epithelization. Prog Clin Biol Res 1991;365:473-480.
10. Ishida Y, Kondo T, Kimura A, et al. Absence of IL-1 receptor antagonist impaired wound healing along with aberrant NF-kB activation and a reciprocal suppression of TGF-beta signal pathway. J Immunol 2006; 176:5598-5606.
11. Uematsu S, Akira S. Toll-like receptors and innate immunity. J Mol Med 2006;84:712-725.
12. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
13. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006;6:823-835.
14. Beutler B. Inferences, questions and possibilities in Toll-like receptor signaling. Nature 2004;430(6996):257-263.
15. Mollen KP, Anand RJ, Tsung A, et al. Emerging paradigm: Toll-like receptor 4-sentinel for the detection of tissue damage. Shock 2006;26:430-437.
16. Wetzler C, Kampfer H, Stallmeyer B, et al. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J Invest Dermatol 2000;115:245-253.
17. Armstrong DG, Lipsky BA. Advances in the treatment of diabetic foot infections. Diabetes Technol Ther 2004;6:167-177.
18. Lipsky BA. Medical treatment of diabetic foot infections. Clin Infect Dis 2004;39(Suppl 2):S104-S114.
19. Miyajima S, Shirai A, Yamamoto S, et al. Risk factors for major limb amputations in diabetic foot gangrene patients. Diabetes Res Clin Pract 2006;71:272-279.
20. Markowitz JS, Gutterman EM, Magee G, et al. Risk of amputation in patients with diabetic foot ulcers: a claims-based study. Wound Repair Regen 2006;14:11-17.
21. Wu KK, Huan Y. Diabetic atherosclerosis mouse models. Atherosclerosis 2007;191:241-249.
22. Like AA, Rossini AA. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 1976;193(4251):415-417.
23. Schein PS, Kahn R, Gordon P, et al. Streptozotocin for malignant insulinomas and carcinoid tumor: report of eight cases and review of the literature. Arch Intern Med 1973;132:555-561.
24. Wilgus TA, Ferreira AM, Oberyszyn TM, et al. Regulation of scar formation by vascular endothelial growth factor. Lab Invest 2008;88:579-590.
25. Dasu MR, Park S, Devaraj S, et al. Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology 2009;150:3457-3464.
26. Dasu MR, Devaraj S, Zhao L, et al. High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes 2008;57:3090-3098.
27. Jialal I, Devaraj S. Low density lipoprotein oxidation, antioxidants, and atherosclerosis: a clinical biochemistry perspective. Clin Chem 1996;42:496-506.
28. Devaraj S, Dasu MR, Rockwood J, et al. Increased Toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 2008;93:578-583.
29. Gill R, Tsung A, Billiar T. Linking oxidative stress to inflammation: Toll-like receptors. Free Radic Biol Med 2010;48:1121-1132.
30. Kim HS, Han MS, Chung KW, et al. Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity 2007;27:321-333.
31. Leemans JC, Stokman G, Claessen N, et al. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest 2005;115:2894-2903.
32. Favre J, Musette P, Douin-Echinard V, et al. Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol 2007;27: 1064-1071.
33. Sakata Y, Dong JW, Vallejo JG, et al. Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2007;292:H503-H509.
34. Greenhalgh DG. Models of wound healing. J Burn Care Rehabil 2005;26:293-305.
35. Greenhalgh DG. Wound healing and diabetes mellitus. Clin Plast Surg 2003;30:37-45.
36. Arbibe L, Mira JP, Teusch N, et al. Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. Nat Immunol 2000;1:533-540.
37. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 2005;115:3149-3156.
38. Drage MG, Pecora ND, Hise AG, et al. TLR2 and its co-receptors determine responses of macrophages and dendritic cells to lipoproteins of Mycobacterium tuberculosis. Cell Immunol 2009;258:29-37.
39. Medzhitov R, Janeway Jr CA. Decoding the patterns of self and nonself by the innate immune system. Science 2002;296:298-300.
40. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-376.
41. Uematsu S, Akira S. Toll-like receptors and innate immunity. J Mol Med 2006;84:712-725.
42. Kawai T, Akira S. TLR signaling. Cell Death Differ 2006;13:8156-8825.
43. Kawai T, Adachi O, Ogawa T, et al. Unresponsiveness of MyD88 deficient mice to endotoxin. Immunity 1999;11:115-122.
44. Macedo L, Pinhal-Enfield G, Alshits V, et al. Wound healing is impaired in MyD88-deficient mice: a role for MyD88 in the regulation of wound healing by adenosine A2A receptors. Am J Pathol 2007;171:1774-1788.
45. Lai Y, Di Nardo A, Nakatsuji T, et al. Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury. Nat Med 2009;15:1377-1382.